N
ARQT icon

Natixis’s Arcutis Biotherapeutics ARQT Stock Holding History

Natixis’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
+12,805
New +$298K ﹤0.01% 890

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Natixis's ARQT Position: Q2 2026 in Review

Natixis opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 12,805 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #890 among its holdings.

272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Natixis held 12,805 shares of Arcutis Biotherapeutics worth $336K as of Q2 2026.
  • Arcutis Biotherapeutics was a new Natixis position in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #890 holding.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.